• 제목/요약/키워드: Targeted gene panel sequencing

검색결과 14건 처리시간 0.029초

The first Korean case with Floating-Harbor syndrome with a novel SRCAP mutation diagnosed by targeted exome sequencing

  • Choi, Eun Mi;Lee, Dong Hyun;Kang, Seok Jin;Shim, Ye Jee;Kim, Heung Sik;Kim, Joon Sik;Jeong, Jong In;Ha, Jung-Sook;Jang, Ja-Hyun
    • Clinical and Experimental Pediatrics
    • /
    • 제61권12호
    • /
    • pp.403-406
    • /
    • 2018
  • Floating-Harbor syndrome is a rare autosomal dominant genetic disorder associated with SRCAP mutation. To date, approximately 50 cases of Floating-Harbor syndrome have been reported, but none have been reported in Korea yet. Floating-Harbor syndrome is characterized by delayed bony maturation, unique facial features, and language impairment. Here, we present a 6-year-old boy with a triangular face, deep-set protruding eyes, low-set ears, wide nose with narrow nasal bridge, short philtrum, long thin lips, clinodactyly, and developmental delay that was transferred to our pediatric clinic for genetic evaluation. He showed progressive delay in the area of language and cognition-adaption as he grew. He had previously undergone chromosomal analysis at another hospital due to his language delay, but his karyotype was normal. We performed targeted exome sequencing, considering several syndromes with similar phenotypes. Library preparation was performed with the TruSight One sequencing panel, which enriches the sample for about 4,800 genes of clinical relevance. Massively parallel sequencing was conducted with NextSeq. An identified variant was confirmed by Sanger sequencing of the patient and his parents. Finally, the patient was confirmed as the first Korean case of Floating-Harbor syndrome with a novel SRCAP (Snf2 related CREBBP activator protein) mutation (c.7732dupT, p.Ser2578Phefs*6), resulting in early termination of the protein; it was not found in either of his healthy parents or a control population. To our knowledge, this is the first study to describe a boy with Floating-Harbor syndrome with a novel SRCAP mutation diagnosed by targeted exome sequencing in Korea.

A novel de novo mosaic mutation in PHEX in a Korean patient with hypophosphatemic rickets

  • Yang, Misun;Kim, Jinsup;Yang, Aram;Jang, Jahyun;Jeon, Tae Yeon;Cho, Sung Yoon;Jin, Dong-Kyu
    • Annals of Pediatric Endocrinology and Metabolism
    • /
    • 제23권4호
    • /
    • pp.229-234
    • /
    • 2018
  • X-linked hypophosphatemic rickets is caused by loss-of-function mutations in PHEX, which encodes a phosphate-regulating endopeptidase homolog. We report a 26-year-old man with X-linked hypophosphatemic rickets who showed decreased serum phosphate accompanied by bilateral genu valgum and short stature. He had received medical treatment with vitamin D (alfacalcidol) and phosphate from the age of 3 to 20 years. He underwent surgery due to valgus deformity at the age of 14 and 15. Targeted gene panel sequencing for Mendelian genes identified a nonsense mutation in PHEX (c.589C>T; p.Gln197Ter) and a mosaic pattern where only 38% of sequence reads showed the variant allele. This mutation was not found in his mother, who had a normal phenotype. This is a case of a sporadic nonsense mutation in PHEX and up to date, this is the first case of a mosaic mutation in PHEX in Korea.

GNPTAB 유전자에서 새로운 돌연변이가 확인된 뮤코지방증 III형 남매 (A Case Report of Novel Mutation in GNPTAB in Two Siblings with Mucolipidosis Type III Alpha/beta)

  • 김민선;박에스더;송아리;임민지;박형두;조성윤;진동규
    • 대한유전성대사질환학회지
    • /
    • 제18권3호
    • /
    • pp.99-106
    • /
    • 2018
  • 뮤코지방증 III alpha/beta는 GNPTAB 유전자의 돌연변이로 야기되는 점액(Mucolipids) 분해 능력 장애이며 상염색체 열성으로 유전된다. 이는 혈액에서 고농축의 점액을 검사하여 진단되며 유전자 검사를 통해 진단을 확인할 수 있다. 뮤코지방증 III형은 희귀하고 점진적으로 진행하는 대사장애로 증상은 3세 경에 나타나며 성장지연, 관절 경직, 관절통, 골격 이상, 심장 판막 이상, 반복되는 호흡기 감염, 평평한 얼굴과 낮은 콧대의 거친 얼굴, 지적장애 또는 학습 문제를 보인다. 본 증례는 성장 지연과 거친 얼굴을 보이는 4세, 2세 7개월 남매에서 targeted gene panel sequencing으로 [c.2715+1G>A (p.Glu906Leufs*4), c.2544del (p. Glu849Lysfs*22)] 두 개의 변이가 이형 접합체로 발견되어 뮤코지방증 III형을 진단하였으며 c.2544del 은 새로운 돌연변이로 대조군에서 발견되지 않았고 표현형과 연관성 고려 시 pathogenic variant로 해석된다. 이와 같이 GNPTAB 유전자에서 새로운 돌연변이가 확인되어 뮤코지방증 III형 남매 증례를 보고하는 바이다. 본 증례처럼 최근 분자유전학적 기술이 발달함에 따라 조기 진단이 가능해지고 진단 후 Case 1 환자에서와 같이 치료를 위하여 pamidronate 투약 가능하나, 이와 같은 보조적 치료 외에도 조기 진단을 받은 뮤코지방증 환자들을 위한 근본적인 치료법 개발을 위한 노력이 필요하다.

  • PDF

신생아 후기에 증상을 발현하여 비교적 양호한 예후를 보이는 Carbamoyl Phosphate Synthetase 1 Deficiency 1례 (A Case of Carbamoyl Phosphate Synthetase 1 Deficiency with a Relatively Good Prognosis Presented in the Late Neonatal Period)

  • 박에스더;김민선;송아리;임민지;장자현;김지혜;조성윤;진동규
    • 대한유전성대사질환학회지
    • /
    • 제18권1호
    • /
    • pp.23-29
    • /
    • 2018
  • Carbamoyl phosphate synthetase 1 (CPS1) 결핍은 고암모니아혈증을 특징으로 하는 요소 회로 이상 질환 중 하나로 상염색체 열성으로 유전되며 2q35 염색체에 존재하는 CPS1 유전자 변이로 인해 발생된다. CPS1 결핍은 발병 연령에 따라 신생아형과 신생아기 이후에 발생하는 지연형으로 나뉜다. CPS1 결핍의 임상 양상의 중증도는 주로 효소 활성 결핍의 정도에 따라 다를 수 있으며, 고암모니아혈증으로 신경 기능 이상 및 장애를 초래하게 된다. 본 증례는 생후 25일 즈음 구토, 의식 저하, 고암모니아혈증을 보여 시행한 생화학적, 분자유전학적 검사(targeted gene panel sequencing)를 통해 CPS1 결핍을 진단하였다. 수액 치료, 관장, 소듐 벤조에이트 치료로 고암모니아혈증 및 임상 양상 호전 보여 응급 투석을 시행하지 않았으며 생후 17개월까지 관찰한 결과 고암모니아혈증의 재발없이 성장과 발달 및 신경학적 예후가 좋음을 보고하는 바이다.

  • PDF